Endometrial cancer
F Amant, P Moerman, P Neven, D Timmerman… - The Lancet, 2005 - thelancet.com
Each year, endometrial cancer develops in about 142 000 women worldwide, and an
estimated 42 000 women die from this cancer. The typical age-incidence curve for …
estimated 42 000 women die from this cancer. The typical age-incidence curve for …
Endometriosis and the development of malignant tumours of the pelvis. A review of literature
T Van Gorp, F Amant, P Neven, I Vergote… - Best practice & research …, 2004 - Elsevier
For several decades, endometriosis has been suspected of playing a role in the aetiology of
ovarian cancer. The literature concerning a possible histogenesis of ovarian cancer from …
ovarian cancer. The literature concerning a possible histogenesis of ovarian cancer from …
Breast cancer in pregnancy: recommendations of an international consensus meeting
PURPOSE: To provide guidance for clinicians about the diagnosis, staging and treatment of
breast cancer occurring during an otherwise uncomplicated pregnancy. METHODS: An …
breast cancer occurring during an otherwise uncomplicated pregnancy. METHODS: An …
MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2− advanced breast cancer who had progressed while receiving endocrine therapy
GW Sledge Jr, M Toi, P Neven, J Sohn… - Journal of clinical …, 2017 - ascopubs.org
Purpose MONARCH 2 (ClinicalTrials. gov identifier: NCT02107703) compared the efficacy
and safety of abemaciclib, a selective cyclin-dependent kinase 4 and 6 inhibitor, plus …
and safety of abemaciclib, a selective cyclin-dependent kinase 4 and 6 inhibitor, plus …
Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies
…, R Paridaens, A Smeets, P Neven… - Journal of the …, 2011 - academic.oup.com
Background Previous studies have suggested that breast cancer risk factors are associated
with estrogen receptor (ER) and progesterone receptor (PR) expression status of the tumors …
with estrogen receptor (ER) and progesterone receptor (PR) expression status of the tumors …
[HTML][HTML] Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study
…, MM Jimenez, S Johnston, F Boyle, P Neven… - Annals of …, 2021 - Elsevier
Background Adjuvant abemaciclib combined with endocrine therapy (ET) previously
demonstrated clinically meaningful improvement in invasive disease-free survival (IDFS) …
demonstrated clinically meaningful improvement in invasive disease-free survival (IDFS) …
[PDF][PDF] Phase III randomized study of ribociclib and fulvestrant in hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast …
DJ Slamon, P Neven, S Chia, PA Fasching… - Journal of Clinical …, 2018 - academia.edu
Purpose This phase III study evaluated ribociclib plus fulvestrant in patients with hormone
receptor–positive/human epidermal growth factor receptor 2–negative advanced breast …
receptor–positive/human epidermal growth factor receptor 2–negative advanced breast …
The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor–positive, ERBB2-negative breast cancer that progressed on endocrine therapy …
GW Sledge, M Toi, P Neven, J Sohn, K Inoue… - JAMA …, 2020 - jamanetwork.com
Importance Statistically significant overall survival (OS) benefits of CDK4 and CDK6
inhibitors in combination with fulvestrant for hormone receptor (HR)–positive, ERBB2 …
inhibitors in combination with fulvestrant for hormone receptor (HR)–positive, ERBB2 …
Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor–positive, human epidermal growth factor receptor 2 …
FC Bidard, VG Kaklamani, P Neven… - Journal of Clinical …, 2022 - ascopubs.org
PURPOSE Patients with pretreated estrogen receptor (ER)–positive/human epidermal
growth factor receptor 2 (HER2)–negative advanced breast cancer have poor prognosis …
growth factor receptor 2 (HER2)–negative advanced breast cancer have poor prognosis …
Parent-of-origin-specific allelic associations among 106 genomic loci for age at menarche
Age at menarche is a marker of timing of puberty in females. It varies widely between
individuals, is a heritable trait and is associated with risks for obesity, type 2 diabetes …
individuals, is a heritable trait and is associated with risks for obesity, type 2 diabetes …